Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Pheochromocytoma 1Paraganglioma 1Neoplasms, Germ Cell and Embryonal 1Gastrointestinal Stromal Tumors 1Carcinoma, Transitional Cell 1

Interventions

Etoposide 17Filgrastim 16Carboplatin 16Ifosfamide 15Peripheral Blood Stem Cell Transplantation 14Cisplatin 14Paclitaxel 12Cyclophosphamide 8Bleomycin 7Radiotherapy 6pegfilgrastim 4Thiotepa 4Flow Cytometry 4etoposide phosphate 3Immunologic Techniques 3sargramostim 2aldesleukin 2Vinblastine 2Temozolomide 2Polymerase Chain Reaction 2Microarray Analysis 2Methylprednisolone 2Magnetic Resonance Spectroscopy 2Immunohistochemistry 2Granisetron 2Gemcitabine 2Dexamethasone 2Busulfan 2Amplified Fragment Length Polymorphism Analysis 2Alemtuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Testicular Germ Cell Tumor × guadecitabine × Genitourinary × Clear all
NCT02429466 2020-09-23

Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors

Indiana University

Phase 1 Completed
14 enrolled
Genitourinary

Testicular Germ Cell Tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡